Press "Enter" to skip to content

Cuba announces that its candidate vaccine Abdala has an efficacy of 92.28% in three doses

The Government of Cuba reported this Monday that its vaccine Abdala, a nationally manufactured anticovid drug, has demonstrated an efficacy of more than 90% in a three-dose scheme, according to the results presented by the Center for Genetic Engineering and Biotechnology (CIGB).

“Abdala reaches 92.28% efficiency with its three-dose scheme and becomes the second of the Cuban vaccine candidates that meet the requirements demanded by the World Health Organization (WHO) to become a vaccine,” said the account presidential office of that body on Twitter.

The Abdala vaccine was developed by the Center for Genetic Engineering and Biotechnology. It is based on the formulation of the RBD protein (Receptor Binding Domain), and uses aluminum hydrogen as an amplifier of the immune response.

The design of the drug uses RBD and the ACE 2 receptor, the main access route of the coronavirus to the cell that infects and causes disease in the individual.

It was recently known that another Cuban candidate against the coronavirus, the Sovereign 02, He showed 62% effective in its two-dose schedule.

Above all obstacles

Within the framework of this announcement, the president of Cuba, Miguel D铆az-Canel, highlighted that scientists from the Finlay Vaccine Institute and the Center for Genetic Engineering and Biotechnology “jumped over all obstacles,” including the pandemic and the blockade. economic against the island, to get “two very effective vaccines“.

Disclaimer: This article is generated from the feed and not edited by our team.